Important drugs for cough in advanced cancer

Jade Homsi, Declan Walsh, Kristine A. Nelson

Research output: Contribution to journalReview article

49 Citations (Scopus)

Abstract

Cough is a defense mechanism that prevents the entry of noxious materials into the respiratory system and clears foreign materials and excess secretions from the lungs and respiratory tract. In advanced cancer, it is a common symptom that interferes with the patient's daily activity and quality of life. Empiric treatment with antitussive agents is often needed. Two classes of antitussive drugs are available: (1) centrally acting: (a) opioids and (b) nonopioids; (2) peripherally acting: (a) directly and (b) indirectly. Antitussive availability varies widely around the world. Many antitussives, such as benzonatate, codeine, hydrocodone, and dextromethorphan, were extensively studied in the acute and chronic cough settings and showed relatively high efficacy and safety profiles. Benzonatate, clobutinol, dihydrocodeine, hydrocodone, and levodropropizine were the only antitussives specifically studied in cancer and advanced cancer cough. They all have shown to be effective and safe in recommended daily dose for cough. In advanced cancer the patient's current medications, previous antitussive use, the availability of routes of administration, any history of drug abuse, the presence of other symptoms and other factors, all have a role in the selection of antitussives for prescription. A good knowledge of the pharmacokinetics, dosage, efficacy, and side effects of the available antitussives provides for better management.

Original languageEnglish (US)
Pages (from-to)565-574
Number of pages10
JournalSupportive Care in Cancer
Volume9
Issue number8
DOIs
StatePublished - Nov 28 2001

Fingerprint

Antitussive Agents
Cough
Pharmaceutical Preparations
Neoplasms
Hydrocodone
Respiratory System
Dextromethorphan
Codeine
Defense Mechanisms
Opioid Analgesics
Substance-Related Disorders
Prescriptions
Pharmacokinetics
Quality of Life
Safety
Lung

Keywords

  • Antitussives
  • Cancer
  • Cough
  • Opioid
  • Palliative

ASJC Scopus subject areas

  • Oncology

Cite this

Important drugs for cough in advanced cancer. / Homsi, Jade; Walsh, Declan; Nelson, Kristine A.

In: Supportive Care in Cancer, Vol. 9, No. 8, 28.11.2001, p. 565-574.

Research output: Contribution to journalReview article

Homsi, Jade ; Walsh, Declan ; Nelson, Kristine A. / Important drugs for cough in advanced cancer. In: Supportive Care in Cancer. 2001 ; Vol. 9, No. 8. pp. 565-574.
@article{13bb6b94dee74b46b519adf8f2261d41,
title = "Important drugs for cough in advanced cancer",
abstract = "Cough is a defense mechanism that prevents the entry of noxious materials into the respiratory system and clears foreign materials and excess secretions from the lungs and respiratory tract. In advanced cancer, it is a common symptom that interferes with the patient's daily activity and quality of life. Empiric treatment with antitussive agents is often needed. Two classes of antitussive drugs are available: (1) centrally acting: (a) opioids and (b) nonopioids; (2) peripherally acting: (a) directly and (b) indirectly. Antitussive availability varies widely around the world. Many antitussives, such as benzonatate, codeine, hydrocodone, and dextromethorphan, were extensively studied in the acute and chronic cough settings and showed relatively high efficacy and safety profiles. Benzonatate, clobutinol, dihydrocodeine, hydrocodone, and levodropropizine were the only antitussives specifically studied in cancer and advanced cancer cough. They all have shown to be effective and safe in recommended daily dose for cough. In advanced cancer the patient's current medications, previous antitussive use, the availability of routes of administration, any history of drug abuse, the presence of other symptoms and other factors, all have a role in the selection of antitussives for prescription. A good knowledge of the pharmacokinetics, dosage, efficacy, and side effects of the available antitussives provides for better management.",
keywords = "Antitussives, Cancer, Cough, Opioid, Palliative",
author = "Jade Homsi and Declan Walsh and Nelson, {Kristine A.}",
year = "2001",
month = "11",
day = "28",
doi = "10.1007/s005200100252",
language = "English (US)",
volume = "9",
pages = "565--574",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Important drugs for cough in advanced cancer

AU - Homsi, Jade

AU - Walsh, Declan

AU - Nelson, Kristine A.

PY - 2001/11/28

Y1 - 2001/11/28

N2 - Cough is a defense mechanism that prevents the entry of noxious materials into the respiratory system and clears foreign materials and excess secretions from the lungs and respiratory tract. In advanced cancer, it is a common symptom that interferes with the patient's daily activity and quality of life. Empiric treatment with antitussive agents is often needed. Two classes of antitussive drugs are available: (1) centrally acting: (a) opioids and (b) nonopioids; (2) peripherally acting: (a) directly and (b) indirectly. Antitussive availability varies widely around the world. Many antitussives, such as benzonatate, codeine, hydrocodone, and dextromethorphan, were extensively studied in the acute and chronic cough settings and showed relatively high efficacy and safety profiles. Benzonatate, clobutinol, dihydrocodeine, hydrocodone, and levodropropizine were the only antitussives specifically studied in cancer and advanced cancer cough. They all have shown to be effective and safe in recommended daily dose for cough. In advanced cancer the patient's current medications, previous antitussive use, the availability of routes of administration, any history of drug abuse, the presence of other symptoms and other factors, all have a role in the selection of antitussives for prescription. A good knowledge of the pharmacokinetics, dosage, efficacy, and side effects of the available antitussives provides for better management.

AB - Cough is a defense mechanism that prevents the entry of noxious materials into the respiratory system and clears foreign materials and excess secretions from the lungs and respiratory tract. In advanced cancer, it is a common symptom that interferes with the patient's daily activity and quality of life. Empiric treatment with antitussive agents is often needed. Two classes of antitussive drugs are available: (1) centrally acting: (a) opioids and (b) nonopioids; (2) peripherally acting: (a) directly and (b) indirectly. Antitussive availability varies widely around the world. Many antitussives, such as benzonatate, codeine, hydrocodone, and dextromethorphan, were extensively studied in the acute and chronic cough settings and showed relatively high efficacy and safety profiles. Benzonatate, clobutinol, dihydrocodeine, hydrocodone, and levodropropizine were the only antitussives specifically studied in cancer and advanced cancer cough. They all have shown to be effective and safe in recommended daily dose for cough. In advanced cancer the patient's current medications, previous antitussive use, the availability of routes of administration, any history of drug abuse, the presence of other symptoms and other factors, all have a role in the selection of antitussives for prescription. A good knowledge of the pharmacokinetics, dosage, efficacy, and side effects of the available antitussives provides for better management.

KW - Antitussives

KW - Cancer

KW - Cough

KW - Opioid

KW - Palliative

UR - http://www.scopus.com/inward/record.url?scp=0035166489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035166489&partnerID=8YFLogxK

U2 - 10.1007/s005200100252

DO - 10.1007/s005200100252

M3 - Review article

C2 - 11762966

AN - SCOPUS:0035166489

VL - 9

SP - 565

EP - 574

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 8

ER -